The anti-tumor potential of robust cGAS-STING pathway activation in GBM has been demonstrated by therapeutic use of the synthetic STING agonist cGAMP that promotes innate and adaptive anti-tumor immunity [33, 70, 71]. The gene discussed is STING1; the disease is neoplasm.